Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
Angiotensin-converting enzyme 2 (ACE2) has been confirmed as a specific receptor for several (3 group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.
1. An isolated angiotensin converting enzyme 2 (ACE2) polypeptide with one or more mutations relative to the wild-type ACE2 that cause the loss of ACE2 enzymatic activity comparing to the wild-type ACE2, the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 3, 4, 10, 17, and 18.
2. A fusion protein comprising an isolated mutated ACE2 polypeptide of claim 1 , further fused to a peptide at N or C terminal of the mutated ACE2 polypeptide, wherein the peptide is capable of binding to a receptor of an immune system associated cell.
3. The fusion protein of claim 2 , wherein the peptide is a ligand binding to a Fc binding receptor (FcγR) on an immune cell of lymphocyte.
4. The fusion protein of claim 3 , wherein the immune cell of lymphocyte is selected from group consisting of T cells, B cells, natural killer cells.
5. The fusion protein of claim 2 , wherein the peptide is a Fc domain of human IgG antibodies (FcΥ).